Toripalimab

DB15043

biotech approved investigational

Deskripsi

The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance. One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)A261506 - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition of T-cell proliferation and cytokine production, and thus its overexpression can inhibit T-cell-mediated immune surveillance of tumors.L48681

Toripalimab is a selective, recombinant, humanized IgG4 monoclonal antibody targeted against the PD-1 receptor. It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients.A262011,A262591 Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.L48696

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean terminal elimination half-life after one dose of toripalimab was 10 ± 1.5 days.[L48681] The mean terminal elimination half-life of toripalimab at steady-state was 18 ± 9.4 days.[L48681]
Volume Distribusi At steady-state, the mean volume of distribution was 3.7 L.[L48681]
Klirens (Clearance) The mean clearance after one dose of toripalimab was 14.9 mL/h.[L48681] The mean clearance of toripalimab at steady-state was 9.5 mL/h.[L48681]

Absorpsi

Steady-state concentrations of toripalimab were reached by week 7 when administered every two weeks.L48681

Metabolisme

As with other therapeutic proteins, toripalimab is likely degraded via catabolic processes into smaller peptides and amino acids.L48681

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Toripalimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Toripalimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Toripalimab.
Estrone Estrone may increase the thrombogenic activities of Toripalimab.
Estradiol Estradiol may increase the thrombogenic activities of Toripalimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Toripalimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Toripalimab.
Mestranol Mestranol may increase the thrombogenic activities of Toripalimab.
Estriol Estriol may increase the thrombogenic activities of Toripalimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Toripalimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Toripalimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Toripalimab.
Tibolone Tibolone may increase the thrombogenic activities of Toripalimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Toripalimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Toripalimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Toripalimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Toripalimab.
Zeranol Zeranol may increase the thrombogenic activities of Toripalimab.
Equol Equol may increase the thrombogenic activities of Toripalimab.
Estetrol Estetrol may increase the thrombogenic activities of Toripalimab.
Promestriene Promestriene may increase the thrombogenic activities of Toripalimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Toripalimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Toripalimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Toripalimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Toripalimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Toripalimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Toripalimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Toripalimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Toripalimab.
Formononetin Formononetin may increase the thrombogenic activities of Toripalimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Toripalimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Toripalimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Toripalimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Toripalimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Toripalimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Toripalimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Toripalimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Toripalimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Toripalimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Toripalimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Toripalimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Toripalimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Toripalimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Toripalimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Toripalimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Toripalimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Toripalimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Toripalimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Toripalimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Toripalimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Toripalimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Toripalimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Toripalimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Toripalimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Toripalimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Toripalimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Toripalimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Toripalimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Toripalimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Toripalimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Toripalimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Toripalimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Toripalimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Toripalimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Toripalimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Toripalimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Toripalimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Toripalimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Toripalimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Toripalimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Toripalimab.
Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Toripalimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Toripalimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Toripalimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Toripalimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Toripalimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Toripalimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Toripalimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Toripalimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Toripalimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Toripalimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Toripalimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Toripalimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Toripalimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Toripalimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Toripalimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Toripalimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Toripalimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Toripalimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Toripalimab.
Stamulumab The risk or severity of adverse effects can be increased when Stamulumab is combined with Toripalimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Toripalimab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Toripalimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Toripalimab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Toripalimab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Toripalimab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Toripalimab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Toripalimab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Toripalimab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Toripalimab.

Target Protein

Programmed cell death protein 1 PDCD1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 35095833
    Zhang L, Hao B, Geng Z, Geng Q: Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666. doi: 10.3389/fimmu.2021.730666. eCollection 2021.
  • PMID: 32266087
    Han Y, Liu D, Li L: PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020 Mar 1;10(3):727-742. eCollection 2020.
  • PMID: 30805896
    Keam SJ: Toripalimab: First Global Approval. Drugs. 2019 Apr;79(5):573-578. doi: 10.1007/s40265-019-01076-2.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Loqtorzi
    Injection • 240 mg/6mL • Intravenous • US • Approved
  • Loqtorzi
    Injection • 240 mg/6mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul